WILD-TYPE in Croatian translation

• divlji tip
• divljeg tipa
• divljim tipom
• divljega tipa

Examples of using Wild-type in English and their translations into Croatian

10 ratio of Ctrough: protein binding-adjusted IC95 for wild-type HIV-1 virus.
IC95 s prilagođenim proteinskim vezivanjem za divlji tip virusa HIV-1.

Tipranavir resistant viruses which emerge in vitro from wild-type HIV-1 show decreased susceptibility to the protease inhibitors amprenavir,
Virusi rezistentni na tipranavir, koji nastaju in vitro iz divljeg tipa HIV-1, pokazuju smanjenu osjetljivost na inhibitore proteaze,

further decreased entecavir susceptibility 16- to 741-fold relative to wild-type virus.
dodatno su smanjile njihovu osjetljivost na entekavir 16 do 741 puta u usporedbi s divljim tipom virusa.

approximately 3.5 hours and the associated cobicistat exposures provide elvitegravir Ctrough approximately 10-fold above the protein-binding adjusted IC95 for wild-type HIV-1 virus.
povezane izloženosti kobicistatu omogućuju Ctrough elvitegravira oko 10 puta višu od prilagođene vrijednosti IC95 vezivanja proteina za divlji tip virusa HIV-1.

clinically relevant EGFRm and T790M mutant NSCLC cell lines with significantly less activity against EGFR in wild-type cell lines.
klinički relevantnih EGFRm i T790M mutantnih NSCLC staničnih linija s značajno manjom aktivnošću protiv EGFR u staničnim linijama divljeg tipa.

Rilpivirine exhibited activity against laboratory strains of wild-type HIV-1 in an acutely infected T-cell line with a median EC50 value for HIV-1/IIIB of 0.73 nM 0.27 ng/ml.
Rilpivirin pokazao je aktivnost protiv laboratorijskih sojeva divljega tipa virusa HIV-1 u akutno zaraženoj T-staničnoj liniji s medijanom vrijednosti EC50 za HIV-1/IIIB od 0, 73 nM 0, 27 ng/ml.

telbivudine showed a susceptibility to tenofovir ranging from 0.7- to 3.4-fold that of wild-type virus.
telbivudin pokazali su 0, 7 do 3, 4 puta veću osjetljivost na tenofovir od divljeg tipa virusa.

Follow-up analysis of boceprevir-treated subjects who did not achieve SVR showed that the population of wild-type virus increased and the majority of boceprevir-resistant variants became undetectable over time after the end of boceprevir treatment.
Naknadna analiza ispitanika liječenih boceprevirom koji nisu postigli trajan virološki odgovor(SVR) pokazala je da se po završetku liječenja boceprevirom populacija virusa divljega tipa povećala i da je većina varijanti rezistentnih na boceprevir s vremenom postala nemjerljiva.

the potential risk of transmission of the varicella vaccine virus should be weighed against the risk of acquiring and transmitting wild-type varicella virus.
treba procijeniti mogući rizik od prijenosa virusa varičele iz cjepiva u odnosu na rizik od dobivanja i prijenosa divljeg tipa virusa varičele.

One of the studies also looked at the results separately in patients whose tumours carried wild-type forms of all RAS genes and patients with mutated
Jedno od ispitivanja je također zasebno istražilo rezultate prikupljene u bolesnika čiji su tumori nosili oblike divljega tipa svih RAS gena

the potential risk of transmission of the influenza vaccine virus should be weighed against the risk of acquiring and transmitting wild-type influenza virus.
potrebno je prosuditi mogući rizik od prijenosa virusa influence iz cjepiva u odnosu na rizik od zaraze i prijenosa divljeg tipa virusa influence.

V600K sequence in a background of wild-type sequence using DNA extracted from FFPE tissue.
V600K sekvenci u pozadini sekvenci divljeg tipa koristeći DNK izoliranu iz FFPE tkiva.

The efficacy and safety of dabrafenib have not been established in patients with wild-type BRAF melanoma therefore dabrafenib should not be used in patients with BRAF wild-type melanoma see sections 4.4 and 5.1.
Djelotvornost i sigurnost dabrafeniba nije ustanovljena u bolesnika s BRAF melanomom divljeg tipa, te se stoga dabrafenib ne smije koristiti u bolesnika s BRAF melanomom divljeg tipa vidjeti dio 4.4 i 5.1.

developing natural zoster and potentially transmitting wild-type VZV to a susceptible contact.
mogućeg prijenosa divljeg tipa virusa varicella-zoster na osjetljivu osobu prilikom kontakta.

P/LAIV H5N1-primed subjects developed vigorous antibody responses to wild-type H5N1 virus upon subsequent exposure to the inactivated H5N1 vaccine, although such antibody responses were not detectable
Ispitanici primarno cijepljeni P/LAIV H5N1 cjepivom razvili su snažan odgovor antitijela na divlji tip virusa H5N1 nakon naknadne izloženosti inaktiviranom cjepivu protiv influence H5N1,

Abacavir-resistant isolates of HIV-1 have been selected in-vitro in wild-type strain HIV-1(HXB2)
Odabrani su izolati HIV-1 koji su bili rezistentni na abakavir in-vitro u divljim sojevima HIV-1(HXB2)

polyneuritis are features of infection with wild-type rubella and vary in frequency
rijetko kronični) i polineuritis znakovi su infekcije divljim tipom virusa rubele i razlikuju se u učestalosti i težini ovisno o dobi

previously untreated patients with wild-type RAS receiving Vectibix in combination with FOLFOX lived for an average of 10.1 months without the disease getting worse compared with 7.9 months for patients receiving FOLFOX alone.
prethodno neliječeni bolesnici s divljim tipom gena RAS koji su primali lijek Vectibix u kombinaciji s„FOLFOX” kemoterapijskim protokolom, živjeli su u prosjeku 10, 1 mjeseci bez pogoršanja bolesti u usporedbi s 7, 9 mjeseci u slučaju bolesnika koji su primali samo FOLFOX.

In the fourth study, previously treated patients with wild-type RAS receiving Vectibix in combination with FOLFIRI lived for 16.2 months compared with 13.9 months in patients receiving FOLFIRI alone.
U četvrtom ispitivanju prethodno liječeni bolesnici s divljim tipom gena RAS koji su primali Vectibix u kombinaciji s FOLFIRI, živjeli su 16, 2 mjeseci u usporedbi s 13, 9 mjeseci u bolesnika koji su primali samo FOLFIRI.

Do not use salicylates in children and adolescents younger than 18 years of age for 4 weeks after vaccination unless medically indicated as Reye's syndrome has been reported following the use of salicylates during wild-type influenza infection.
Nemojte davati salicilate djeci i adolescentima mlađima od 18 godina tijekom 4 tjedna nakon cijepljenja osim ako to nije medicinski indicirano, jer je nakon primjene salicilata tijekom infekcije divljim tipom virusa influence zabilježen Reyev sindrom.